---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-048527"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:30:37.971536+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50

## Summary
- Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.
- Gross proceeds expected to be approximately $200M before expenses; net proceeds plus existing cash expected to fund operations into H2 2028.
- Underwriters: Jefferies, Goldman Sachs, Evercore, Guggenheim; closing expected Nov 20, 2024.
- Offered pursuant to Form S-3 shelf registration; prospectus supplement filed Nov 19, 2024.

## SEC filing metadata
- accession: 0001628280-24-048527
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000162828024048527/0001628280-24-048527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000162828024048527/syre-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-048527
- JSON: https://secwatch.observer/filing/0001628280-24-048527.json
- Plain text: https://secwatch.observer/filing/0001628280-24-048527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.